One of the most interesting things I learned in the Dr. Yo interview is the White paper DP just put out on cancer targets for Leronlimab. He mentioned identifying a ranking types of tumors expressing CCR5 including a number of them with a higher rank than triple negative breast cancer, like bladder and prostate cancer. This is very exciting work and the stuff that says "bet the farm" to me.

This is also an example against NP comments saying CYDY does not need research (as blafarm already mentioned). It would be wise for NP to retract that statement, but I think we know the emphasis he was trying to make.